Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Ziresovir in Healthy Men
NCT03400995Phase 1Completed
- Sponsor
- Ark Biosciences
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ziresovir in respiratory syncytial virus infection (RSV), sponsored by Ark Biosciences. Primary endpoints: Amount excreted at 6 weeks, Percentage of the administered dose excreted at 6 weeks and 2 more. Started Jan 2018; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03400995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400995.